Dr. Matthew Hewitt has held roles in research and development over the past 10 years in both academia and industry. Over that time he has built and run successful programs in pre-clinical, IND-enabling, and clinical support settings using his extensive immunology and molecular biology experience.
Dr. Hewitt is currently Director of the Tumor Immunology & Microenvironment group at Bellicum Pharmaceuticals. His group focuses on understanding the underlying immunology of the tumour microenvironment and examines avenues to overcome it to increase CAR-T efficacy in solid tumours.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October